<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04904835</url>
  </required_header>
  <id_info>
    <org_study_id>DC-TR18-0408</org_study_id>
    <secondary_id>HBV-EU-08-19</secondary_id>
    <nct_id>NCT04904835</nct_id>
  </id_info>
  <brief_title>Access HBV Assays - European Union (EU) Clinical Trial Protocol -</brief_title>
  <official_title>Evaluation of the Beckman Coulter Access Hepatitis B Virus (HBV) Serological Marker Assays as an Aid in the Diagnosis of HBV Infection: EU Clinical Trial Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beckman Coulter, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beckman Coulter, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this protocol is the collection and testing of clinical samples to determine&#xD;
      the clinical performance of the Access HBV serological marker assays on the DxI 9000 Access&#xD;
      Immunoassay Analyzer.&#xD;
&#xD;
      The study will involve a multicenter, prospective and retrospective collection of samples,&#xD;
      and testing of samples with the investigational Hepatitis B Virus assays as required per the&#xD;
      European Union Common Technical Specification. All samples collected will be anonymized or&#xD;
      pseudo-anonymised, leftover, remnant samples. Pseudo-anonymised collection of samples will&#xD;
      require documented patient consent (oral or written).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sensitivity to final status on presumed HBV serological marker positive subjects will be&#xD;
      calculated. Specificity will be calculated from hospitalized patients and blood donors&#xD;
      specimens. False Initial Reactive Rate will be calculated on fresh hospitalized patient&#xD;
      samples for Access HBsAg assay only (Qualitative).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 15, 2019</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic accuracy measured as sensitivity and specificity</measure>
    <time_frame>Baseline</time_frame>
    <description>The endpoint will be diagnostic accuracy measured as sensitivity and specificity of Access HBV serological assays compared to sample status determined by specific testing algorithm for each HBV marker</description>
  </primary_outcome>
  <number_of_groups>10</number_of_groups>
  <enrollment type="Anticipated">21210</enrollment>
  <condition>HBV</condition>
  <arm_group>
    <arm_group_label>Unselected blood donors</arm_group_label>
    <description>leftover samples from unselected blood donors from at least 2 donation centers. Leftover samples to be tested by Access HBV serological marker assays and CE-marked (european compliance marked) predicate assays</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hospitalized patients</arm_group_label>
    <description>Leftover samples to be tested by Access HBV serological marker assays and CE-marked predicate assays</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Presumed HBsAg positive patients</arm_group_label>
    <description>Leftover samples from patients at different stages of HBV infection (acute and chronic, minimum 10 per stage of infection), HBsAg positive by a Confirmatory testing of a CE-marked assay, including ≥ 25 &quot;same day&quot; fresh samples (tested ≤1 day after sampling), and minimum 20 high positive samples (&gt;26 IU/mL) and minimum 20 samples in the cut-off range. If not enough samples in the cut-off range are obtained during the clinical trial, additional HBsAg specimens in the cut-off range will be tested by Research &amp;Development to fit with Common Technical Specification requirements.&#xD;
Leftover samples to be tested by Access HBsAg assays and CE-marked predicate assays</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients having recovered from natural HBV infection, presumed Anti-HBs positive</arm_group_label>
    <description>Leftover samples from Patients positive for Anti-HBs and Anti-HBc Total by CE-marked assays. Target is to have at least ¾ of them recovered without HBV antiviral treatment.&#xD;
Leftover samples to be tested by Access anti-HBs assay and CE-marked predicate assays</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients having received HBV vaccination, presumed Anti-HBs positive</arm_group_label>
    <description>Leftover samples Confirmed as vaccinated by testing at the time of enrollment (i.e. positive for Anti-HBs and negative for Anti-HBc by CE-marked assays).Leftover samples to be tested by Access anti-HBs assay and CE-marked predicate assays</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Presumed Anti-HBc Total positive patients</arm_group_label>
    <description>Leftover samples from Patients at different stage of infection (acute, chronic or recovered, minimum 10 per stage of infection) positive for Anti-HBc Total by a CE-marked assay, including ≥ 25 &quot;same day&quot; fresh samples (tested ≤1 day after sampling).&#xD;
Leftover samples to be tested by Access anti-HBc Total and CE-marked predicate assays</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Presumed Anti-HBc IgM positive patients</arm_group_label>
    <description>left over samples from Patients with acute/recent HBV infection, positive for Anti-HBc IgM by a CE-marked assay.&#xD;
Leftover samples to be tested by Access anti-HBc IgM assay and CE-marked predicate assays</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Presumed HBeAg positive patients</arm_group_label>
    <description>Leftover samples from Patients at different stages of infection (acute and chronic, minimum 5 per stage of infection), positive for HBeAg by a CE-marked assay.&#xD;
Leftover samples to be tested by Access HBeAg assay and CE-marked predicate assays</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Presumed Anti-HBe positive patients7</arm_group_label>
    <description>Leftover samples from Patients at different stages of infection (chronic and recovered, minimum 5 per stage of infection), positive for Anti-HBe by a CE-marked assay.&#xD;
Leftover samples to be tested by Access anti-HBe assay and CE-marked predicate assays</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with chronic HBV infection</arm_group_label>
    <description>Leftover samples to be tested by Access anti-HBc IgM assay and CE-marked predicate assay</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Access HBV serological marker assays on the DxI 9000 Access Immunoassay Analyzer and CE-marked predicate assays</intervention_name>
    <description>All samples will be tested with both CE-marked HBV serological predicate assays (HBsAg, HBsAb, HBcT, HBc IgM, HBeAb, and/or HBeAg assays) and Access HBV serological assays (HBsAg, HBsAb, HBcT, HBc IgM, HBeAb, and/or HBeAg assays) according to respective Instructions For Use to determine non-reactive (NR), initially reactive (IR), repeatedly reactive (RR), or confirmed or not confirmed Positive.</description>
    <arm_group_label>Hospitalized patients</arm_group_label>
    <arm_group_label>Patients having received HBV vaccination, presumed Anti-HBs positive</arm_group_label>
    <arm_group_label>Patients having recovered from natural HBV infection, presumed Anti-HBs positive</arm_group_label>
    <arm_group_label>Patients with chronic HBV infection</arm_group_label>
    <arm_group_label>Presumed Anti-HBc IgM positive patients</arm_group_label>
    <arm_group_label>Presumed Anti-HBc Total positive patients</arm_group_label>
    <arm_group_label>Presumed Anti-HBe positive patients7</arm_group_label>
    <arm_group_label>Presumed HBeAg positive patients</arm_group_label>
    <arm_group_label>Presumed HBsAg positive patients</arm_group_label>
    <arm_group_label>Unselected blood donors</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The test population includes :&#xD;
&#xD;
          1. 16,400 Unselected blood donors from at least 2 donation centers&#xD;
&#xD;
          2. 2,700 Hospitalized patients&#xD;
&#xD;
          3. 450 Presumed HBsAg positive patients&#xD;
&#xD;
          4. 150 Patients having recovered from natural HBV infection, presumed Anti-HBs positive&#xD;
&#xD;
          5. 300 Patients having received HBV vaccination, presumed Anti-HBs positive&#xD;
&#xD;
          6. 450 Presumed Anti-HBc Total positive patients&#xD;
&#xD;
          7. 220 Presumed Anti-HBc IgM positive patients 8-220 Presumed HBeAg positive patients&#xD;
&#xD;
        9- 220 Presumed Anti-HBe positive patients 10- 100 Patients with chronic HBV infection&#xD;
        TOTAL n=21,210&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject aged ≥ 18 years,&#xD;
&#xD;
          -  Subject who has provided consent (oral or written) or sample collected under waiver&#xD;
&#xD;
          -  With sufficient volume to perform clinical trial testing&#xD;
&#xD;
          -  And belonging to one of the following enrollment groups:&#xD;
&#xD;
               -  Unselected blood donors&#xD;
&#xD;
               -  Hospitalized patients&#xD;
&#xD;
               -  Presumed HBsAg positive patients by Confirmatory testing of a CE-marked assay&#xD;
&#xD;
               -  Patients having recovered from natural HBV infection, presumed Anti-HBs positive&#xD;
                  (i.e. Anti-HBs and Anti-HBc Total positive by CE-marked assays)&#xD;
&#xD;
               -  Patients having received HBV vaccination, presumed Anti-HBs positive (confirmed&#xD;
                  by testing at the time of enrollment, i.e. positive for Anti-HBs and negative for&#xD;
                  Anti-HBc by CE-marked assays).&#xD;
&#xD;
               -  Presumed Anti-HBc Total positive patients by a CE-marked assay&#xD;
&#xD;
               -  Presumed Anti-HBc IgM positive patients by a CE-marked assay with acute/recent&#xD;
                  HBV infection 8&#xD;
&#xD;
               -  Presumed HBeAg positive patients by a CE-marked assay&#xD;
&#xD;
               -  Presumed Anti-HBe positive patients by a CE-marked assay&#xD;
&#xD;
               -  Patients with chronic HBV infection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Samples from subjects already included in the study* (* Patient can be included only&#xD;
             once per HBV marker study, but can potentially be enrolled for several separate HBV&#xD;
             marker studies.)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Juliane HEY, Dr</last_name>
    <phone>+33 645 23 81 74</phone>
    <email>jhey@beckman.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre de Ressources Biologiques Biobanque de Picardie CHU Amiens-Picardie</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yves-Edouard Herpe, Dr</last_name>
      <phone>+33 322 08 93 60</phone>
      <email>Herpe.Yves-Edouard@chu-amiens.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Etablissement Français du Sang (EFS) Hauts-de-France - Normandie</name>
      <address>
        <city>Bois Guillaume</city>
        <zip>76232</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sandrine Gréaume, Dr</last_name>
      <phone>+33 2 32 80 09 60</phone>
      <email>Sandrine.greaume@efs.sante.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Eurofins Biomnis</name>
      <address>
        <city>Ivry-sur-Seine</city>
        <zip>94208</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Coignard, MD</last_name>
      <phone>+33 149 59 63 37</phone>
      <email>catherine.coignard@biomnis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Laboratoire de Virologie, Laboratoire associé au CNR du VIH Institut de Biologie Clinique ; hôpital C : Nicolle, CHU Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Christophe Plantier, Pr</last_name>
      <phone>02 32 88 14 62</phone>
      <email>jc.plantier@chu-rouen.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cerba Xpert</name>
      <address>
        <city>St Ouen l'Aumone</city>
        <zip>95310</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jérémie Gautier, PhD</last_name>
      <phone>+33 1 34 40 98 16</phone>
      <email>jeremie.gautier@cerbaxpert.com</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 18, 2021</study_first_submitted>
  <study_first_submitted_qc>May 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 27, 2021</study_first_posted>
  <last_update_submitted>May 25, 2021</last_update_submitted>
  <last_update_submitted_qc>May 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis B surface Antigen (HBsAg)</keyword>
  <keyword>Total hepatitis B core Antibody (HBcT)</keyword>
  <keyword>Hepatitis B e Antigen (HBeAg)</keyword>
  <keyword>Hepatitis B e Antibody (HBeAb)</keyword>
  <keyword>Hepatitis B surface Antibody (HBsAb)</keyword>
  <keyword>IgM Antibody to hepatitis B core Antigen (HBc IgM)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

